Angelalign 6699

[winston]

not vested

ANGELALIGN(6699)

Analysis：

Angelalign is a leading provider of invisible orthodontic treatment solutions in China.

It has successively launched four invisible orthodontic products:
1. Angelalign Standard Edition
2. Angelalign Champion Edition
3. COMFOS and
4. Angelalign Children`s Edition

In 2021, its market share will be 40%, the market share will be the first, and the product line will be the most comprehensive.

The size of China`s invisible appliance market will increase from US$200 million in 2015 to US$1.5 billion in 2020, with a compound annual growth rate of 44.4%.

The domestic invisible orthodontic industry can still maintain rapid growth.

The epidemic prevention policy has affected the normal business development of some medical institutions.

In the first half of the year, the company`s revenue fell by 0.09% year-on-year, and the net profit attributable to the parent was 70 million yuan, down 22.7% year-on-year.

The company continued to rapidly increase the coverage rate of new markets, and the proportion of cases contributed by third- and fourth-tier cities in the first half of the year increased steadily.

As the impact of the epidemic dissipates, the market demand for invisible orthodontics will continue to recover.

Strategy：
Buy-in Price: $70.00, Target Price: $87.00, Cut Loss Price: $61.00

Source: Phillips

[winston]

not vested

ANGELALIGN(6699)

Analysis：
Angelalign is a leading provider of invisible orthodontic treatment solutions in China.

It has successively launched four invisible orthodontic products:
1. Angelalign Standard Edition
2. Angelalign Champion Edition
3. COMFOS and
4. Angelalign Children's Edition.

In 2021, its market share will be 40%, the market share will be the first and the product line will be the most comprehensive.

The size of China's invisible appliance market will increase from US$200 million in 2015 to US$1.5 billion in 2020, with a compound annual growth rate of 44.4%.

The domestic invisible orthodontic industry can still maintain rapid growth.

The epidemic prevention policy has affected the normal business development of some medical institutions.

In the first half of the year, the company's revenue fell by 0.09% year-on-year, and the net profit attributable to the parent was 70 million yuan, down 22.7% year-on-year.

The company continued to rapidly increase the coverage rate of new markets, and the proportion of cases contributed by third- and fourth-tier cities in the first half of the year increased steadily.

As the impact of the epidemic dissipates, the market demand for invisible orthodontics will continue to recover.

Strategy：
Buy-in Price: $109.00, Target Price: $130.00, Cut Loss Price: $98.00

Source: Phillips